

Appendix 1: Candidates for the Board of Directors

*Listed companies



Georges Gemayel Chairman

Member since: 2012 (Chairman since 2014)
Born in: 1960
Nationality: American
Committees: Nomination Committee (Chairman)

Special competences

Dr. Gemayel's qualifications to sit on the Board of Directors include his significant management and executive experience in the global pharmaceutical industry.

Other management duties

Georges Gemayel is currently Chairman of the Board of Directors of Dynacure SAS, Enterome SA, and OxThera AB and a member of the Board of Directors of Momenta Pharmaceuticals Inc. (publ)* and Supernus Pharmaceuticals Inc. (publ)*.

Previous positions

Georges Gemayel has previously been Chairman of the Board of Directors of Dimension Therapeutics Inc. (publ), Epitherapeutics ApS, Vascular Magnetics Inc., and Syndexa Pharmaceuticals Inc. as well as a member of the Board of Directors of NPS Pharmaceuticals Inc. (publ), Raptor Pharmaceuticals Corp. (publ), Prosenza N.V. (publ), and Adolor Corp. (publ).

Educational background

Georges Gemayel holds a Master and a PhD in Pharmacology from Paris-Sud University and a Docteur d'Exercice en Pharmacie from the St. Joseph University.



Bo Jesper Hansen Deputy Chairman

Member since: 2010 (Deputy Chairman since 2017)
Born in: 1958
Nationality: Danish
Committees: Remuneration Committee (Chairman)

Special competences

Dr. Hansen's extensive experience in orphan drugs, both from the operations and supervisory point of view and his broad and current know-how of the biotechnology environment makes him a qualified member of the Board of Directors.

Other management duties

Bo Jesper Hansen is currently Chairman of the Board of Directors of Laborie Inc., Innoventa Medica ApS, and Karo Pharma AB and a member of the Board of Directors of Azanta A/S and Ascelia Pharma AB.

Previous positions

Bo Jesper Hansen has previously been Chairman of the Board of Directors and a member of the Executive Management of Swedish Orphan Biovitrum AB (publ), Chairman of the Board of Directors of Ablynx NV, Reaplix ApS, Topotarget A/S (publ) (dissolved by merger), Karolinska Development AB (publ) and a member of the Board of Directors of Newron Pharmaceuticals SpA, CMC Sweden AB, Hyperion Therapeutics Inc. (publ) (dissolved following acquisition), Gambro AB, Inspyr Inc. (publ), Zymenex Holding A/S, Zymenex A/S, ACE Bioscience A/S, Mipsalus Holding ApS, and MipSalus ApS.

Educational background

Bo Jesper Hansen holds an MD and PhD in Medicine from the University of Copenhagen.



Anders Hedegaard

Member since: 2017
Born in: 1960
Nationality: Danish
Committees: Remuneration Committee

Special competences

Mr. Hedegaard is a sitting Chief Executive Officer of a publicly listed company. His extensive knowledge of the healthcare industry, both in product development and commercialization, makes him a qualified member of the Board of Directors.

Other management duties

Anders Hedegaard is currently Chief Executive Officer of Rodenstock Group and Chairman of the Board of Directors of Rodenstock Danmark A/S. Anders Hedegaard is also recommended as the Chairman of the Board of Directors of ALK-Abelló A/S (publ)* from March 2020.

Previous positions

Anders Hedegaard has previously been Chairman of the Board of Directors of GN Otometrics A/S, Aktieselskabet af 1. juni 2011 I, and BN Washington D.C. Holding A/S as well as a member of the Board of Directors of the Confederation of Danish Enterprise, Hearing Instrument Manufacturers Software Association A/S, HIMSA II A/S, Origio A/S and certain companies in or associated with the Bavarian Nordic Group. Further, Anders Hedegaard has previously been Chief Executive Officer of GN Store Nord A/S (publ), GN Hearing A/S, and Bavarian Nordic A/S and a member of the Executive Management of ALK-Abelló A/S and FOSS A/S as well as international marketing director at Novo Nordisk A/S.

Educational background

Anders Hedegaard holds a Master of Science in Chemical Engineering and Biochemistry from the Technical University of Denmark.



Catherine Moukheibir

Member since: 2017
Born in: 1957
Nationality: American, Lebanese, and British
Committees: Audit Committee (Chairman)

Special competences

Ms Moukheibir's experience in the pharmaceutical and banking industries and her successful track record in leading Audit Committees of publicly traded companies makes her a qualified member of the Board of Directors.

Other management duties

Catherine Moukheibir is currently Chairman of the Board of Directors and Chief Executive Officer of MedDay Pharmaceuticals SA as well as member of the Board of Directors of Genkyotex SA (publ)*, Ironwood Pharmaceuticals, Inc., and Kymab Ltd.

Previous positions

Catherine Moukheibir has previously been a member of the Executive Management for Innate Pharma Inc (publ), Chairman of the Board of Directors of Creabilis and a member of the Board of Directors in Zealand Pharma A/S (publ), Ablynx NV (publ), Cerenis Therapeutics SA (publ), and Octopus NV.

Educational background

Catherine Moukheibir holds a Master in Economics and an MBA degree, both from Yale University.



Martijn Kleijwegt

Member since: 2017
Born in: 1955
Nationality: Dutch
Committees: Audit Committee

Special competences

Mr. Kleijwegt is qualified to serve on the Board of Directors given his experience as a major European venture-capital investor, his experience in the pharmaceutical industry, and his service on the Boards of Directors of other biopharmaceutical companies.

Other management duties

Martijn Kleijwegt is currently Founder and Managing Partner at LSP Management Group BV and a member of the Board of Directors of AM Pharma BV, Kiadis Pharma N.V. (publ)*, OxThera AB, Eloxx Pharmaceuticals Ltd., and Pharvaris BV.

Previous positions

Martijn Kleijwegt has previously been a member of the Board of Directors of Prosensa N.V. (publ).

Educational background

Martijn Kleijwegt holds a Master's degree from the University of Amsterdam.



Martin Bonde

Member since: 2010
Born in: 1963
Nationality: Danish
Committees: Nomination Committee

Special competences

Dr. Bonde's qualifications to sit on the Board of Directors include his executive experience and in-depth knowledge of the biotechnology environment in the Nordic countries.

Other management duties

Martin Bonde is currently Entrepreneur-in-Residence at BiOrigin ApS, a Novo Seeds company. Martin Bonde is also a member of Board of Directors of Visiopharm A/S, Chief Executive Officer of Bohrs Tower ApS as well as a member of the Board of Directors and the Executive Management of Biotopix ApS.

Previous positions

Martin Bonde has previously been the Chairman of the Board of Directors of DANSK BIOTEK and a member of the Executive Management of Vaccibody AS and Epitherapeutics ApS.

Educational background

Martin Bonde holds a Graduate Diploma in Business Administration from Copenhagen Business School, a Master of Science, and a PhD in Chemical Engineering from the Technical University of Denmark.



Rémi Droller

Member since: 2015
Born in: 1975
Nationality: French
Committees: Remuneration Committee

Special competences

Mr. Droller's extensive experience as a biotechnology investor and his proven track-record in negotiating several successful transactions make him a qualified member of the Board of Directors.

Other management duties

Rémi Droller is currently Managing Partner of Kurma Partners SA and member of the Board of Directors of Dynacure SAS, ImCheck Therapeutics SAS, OxThera AB, AM Pharma BV, Pharvaris BV, Flamingo Therapeutics BV, and Vico Therapeutics BV.

Previous positions

Rémi Droller has previously been Chairman of the Board of Directors of Step Pharma SAS and a member of the Board of Directors of Prosensa N.V. (publ), and Onxeo SA (publ).

Educational background

Rémi Droller holds a Master in Molecular Biology from Université Pierre et Marie Curie and a Master in Finance and Management of Innovation from Masternova.



Sten Verland

Member since: 2010
Born in: 1957
Nationality: Danish
Committees: Nomination Committee, Audit Committee

Special competences

Dr. Verland is a serial entrepreneur in biotechnology companies. He has extensive investment and managerial experience that make him a qualified member of the Board of Directors.

Other management duties

Sten Verland is currently Co-Founder and member of the Board of Directors of Sunstone Capital A/S, member of the Board of Directors and General Partner at Sunstone Life Science Ventures A/S, a member of the Board of Directors of STipe Therapeutics ApS, Anergis SA, MinervaX ApS, OxThera AB, the Danish Venture Capital and Private Equity Association (DVCA) as well as a member of the Board of Directors and Executive Management in certain companies in, or associated with, the Sunstone group. Sten Verland is also currently a member of the Executive Management of Verland Capital ApS, Verland Holding ApS, Verland Holding II ApS, and Genobiotix ApS.

Previous positions

Sten Verland has previously been a member of the Board of Directors of F2G Ltd., Vaximm AG, Rigontec GmbH, Selskabet af 9. september 2015 A/S and Selskabet af 23. september 2015 ApS, a member of the Board of Directors and Chief Executive Officer of VetVerland ApS as well as a General Partner and a member of the Board of Directors and Executive Management in certain companies in or associated with the Sunstone group.

Educational background

Sten Verland holds a Master in Biology and Mathematics and a PhD in Immunology from the University of Copenhagen.